Monday, December 23, 2024
HomeTagsAnti-Resistance Therapeutic

Anti-Resistance Therapeutic

Bold Therapeutics Extends South Korea Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics